Miguel Ángel Royo Bordonadaa, Pedro Armariob, José María Lobos Bejaranoc, Juan Pedro Botetd, Fernando Villar Álvareze, Roberto Elosuaf, Carlos Brotonsg, Olga Cortés Ricoh, Benilde Serranoi, Miguel Camafortj, Antonio Gil Núñezk, Antonio Pérezl, Antonio Maiques Galánm, Ana de Santiago Nociton, Almudena Castroo, Eduardo Alegría Ezquerrap, Ciro Baezaq, María Herranzr, Susana Sanss, (CEIPC) en nombre del Comité Español Interdisciplinario para la Prevención Cardiovasculart
aInstituto de Salud Carlos III. Madrid. España.
bSociedad Española-Liga Española para la Lucha contra la Hipertensión Arterial .
cSociedad Española de Medicina de Familia y Comunitaria.
dSociedad Española de Arteriosclerosis .
eSociedad Española de Arteriosclerosis.
fSociedad Española de Epidemiología (SEE).
gSociedad Española de Medicina Familiar y Comunitaria (SemFYC) .
hPediatra. CS Canillejas. Madrid. España.
iSociedad Española de Medicina y Seguridad en el Trabajo.
jSociedad Española de Medicina Interna.
kSociedad Española de Neurología .
lSociedad Española de Diabetes.
mSociedad Española de Medicina de Familia y Comunitaria. Madrid. España.
nSociedad Española de Médicos de Atención Primaria-Semergen .
oSociedad Española de CardiologíaeSociedad Española de Cardiología-Coordinadora Nacional Sección de Prevención.
pSección de Riesgo Vascular y Rehabilitación Cardiaca. Sociedad Española de Cardiología. Madrid. España.
qSociedad Española de Angiología y Cirugía Vascular.
rFederación de Asociaciones de Enfermería Comunitaria y Atención Primaria (FAECAP).
sSociedad Española de Salud Pública y Administración Sanitaria.
tComité Español Interdisciplinario para la Prevención Cardiovascular.
Reference of this article: Royo Bordonada MA, Armario P, Lobos Bejarano JM, Pedro Botet J, Villar Álvarez F, Elosua R, et al. Spanish adaptation of the 2016 European guidelines on cardiovascular disease prevention in clinical practice. Rev Pediatr Aten Primaria. 2017;19:e1-e25.
Published in Internet: 13-01-2017 - Visits: 16557
Abstract
The VI European Guidelines for Cardiovascular Prevention recommend combining population and high-risk strategies with lifestyle changes as a cornerstone of prevention, and propose the SCORE function to quantify cardiovascular risk. The guidelines highlight disease specific interventions, and conditions specific to women, young people and ethnic minorities. Screening for subclinical atherosclerosis with noninvasive imaging techniques is not recommended. The guidelines distinguish four risk levels (very high, high, moderate and low) with therapeutic objectives for lipid control according to risk. Diabetes mellitus confers a high risk, except for subjects with type 2 diabetes with less than ten years of evolution, with no other risk factors or complications, or type 1 diabetes of short evolution without complications. The decision to start pharmacological treatment of arterial hypertension will depend on the blood pressure level and cardiovascular risk, taking into account the lesion of target organs. The guidelines do not recommend antiplatelet drugs in primary prevention because of the increased risk of bleeding. The low adherence to the medication requires simplified therapeutic regimes and identifying and combating its causes. The guidelines highlight the responsibility of health professionals to play an active role in promoting evidence-based interventions at the population level, and propose effective interventions, both at individual and population level, to promote a healthy diet, the practice of physical activity, the cessation of smoking and the protection against alcohol abuse..
Keywords
● Alcohol drinking ● Arterial hypertension ● Cardiovascular diseases ● Cholersterol ● Clinical practice guidelines ● Diabetes mellitus ● Prevention and control ● Smoking ● Trans fatty acids
Comments
This article has no comments yet.